Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) shot up 4.5% during mid-day trading on Thursday . The stock traded as high as $22.36 and last traded at $22.22. 122,911 shares were traded during mid-day trading, a decline of 47% from the average session volume of 230,251 shares. The stock had previously closed at $21.25.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on ELVN shares. Robert W. Baird increased their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, November 15th. BTIG Research started coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a "buy" rating and a $42.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $38.25.
Read Our Latest Research Report on Enliven Therapeutics
Enliven Therapeutics Trading Down 2.3 %
The business has a 50-day moving average of $21.84 and a 200 day moving average of $23.90. The firm has a market capitalization of $1.00 billion, a P/E ratio of -10.76 and a beta of 1.04.
Insider Activity
In other news, CFO Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Anish Patel sold 21,700 shares of the company's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00. The disclosure for this sale can be found here. Insiders sold a total of 41,117 shares of company stock worth $949,435 over the last quarter. 29.20% of the stock is currently owned by corporate insiders.
Institutional Trading of Enliven Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of ELVN. Quest Partners LLC grew its holdings in Enliven Therapeutics by 1,226.4% during the third quarter. Quest Partners LLC now owns 21,117 shares of the company's stock worth $539,000 after buying an additional 19,525 shares in the last quarter. First Turn Management LLC lifted its position in shares of Enliven Therapeutics by 29.5% during the third quarter. First Turn Management LLC now owns 535,092 shares of the company's stock valued at $13,666,000 after purchasing an additional 121,849 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Enliven Therapeutics by 10.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company's stock worth $6,520,000 after purchasing an additional 24,043 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Enliven Therapeutics by 25.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company's stock worth $441,000 after purchasing an additional 3,518 shares in the last quarter. Finally, FMR LLC increased its stake in Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company's stock valued at $160,804,000 after buying an additional 601,611 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
